Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Corey Hebert

Showing results (1-10 of 5) with videos related to

Pageof 1
Sort By:
The Virtual Mentor : VM|November 10, 2012
Rebuilding medicineCorey Hebert
Cureus|June 11, 2025
Effect of Chemotherapy Treatment on Overall Survival of Colon Cancer Patients Using Propensity Score MatchingCorey Hebert, Lawerence Shi, Runhua Shi
Open Forum Infectious Diseases|May 2, 2022
Bamlanivimab and Etesevimab Improve Symptoms and Associated Outcomes in Ambulatory Patients at Increased Risk for Severe Coronavirus Disease 2019: Results From the Placebo-Controlled Double-Blind Phase 3 BLAZE-1 TrialPeter Chen, Gerhard Behre, Corey Hebert, et al.
The New England Journal of Medicine|July 14, 2021
Bamlanivimab plus Etesevimab in Mild or Moderate Covid-19Michael Dougan, Ajay Nirula, Masoud Azizad, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|October 31, 2021
A Randomized, Placebo-Controlled Clinical Trial of Bamlanivimab and Etesevimab Together in High-Risk Ambulatory Patients With COVID-19 and Validation of the Prognostic Value of Persistently High Viral LoadMichael Dougan, Masoud Azizad, Bharat Mocherla, et al.
Pageof 1

Showing results (1-10 of 5) with videos related to

Sort By:
Pageof 1
The Virtual Mentor : VM|November 10, 2012
Rebuilding medicineCorey Hebert
Cureus|June 11, 2025
Effect of Chemotherapy Treatment on Overall Survival of Colon Cancer Patients Using Propensity Score MatchingCorey Hebert, Lawerence Shi, Runhua Shi
Open Forum Infectious Diseases|May 2, 2022
Bamlanivimab and Etesevimab Improve Symptoms and Associated Outcomes in Ambulatory Patients at Increased Risk for Severe Coronavirus Disease 2019: Results From the Placebo-Controlled Double-Blind Phase 3 BLAZE-1 TrialPeter Chen, Gerhard Behre, Corey Hebert, et al.
The New England Journal of Medicine|July 14, 2021
Bamlanivimab plus Etesevimab in Mild or Moderate Covid-19Michael Dougan, Ajay Nirula, Masoud Azizad, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|October 31, 2021
A Randomized, Placebo-Controlled Clinical Trial of Bamlanivimab and Etesevimab Together in High-Risk Ambulatory Patients With COVID-19 and Validation of the Prognostic Value of Persistently High Viral LoadMichael Dougan, Masoud Azizad, Bharat Mocherla, et al.
Pageof 1